Summary of clinical trials with zafirlukast

被引:32
作者
Calhoun, WJ [1 ]
机构
[1] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA
关键词
D O I
10.1164/ajrccm.157.6.mar6
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma, In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events, Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma.
引用
收藏
页码:S238 / S246
页数:9
相关论文
共 31 条
[1]  
BOULET LP, 1996, EUR RESP J S23, V9, pS273
[2]  
CALHOUN WJ, 1997, AM J RESP CRIT CARE, V155, pA662
[3]  
CALHOUN WJ, IN PRESS AM J RESP C
[4]   THE LEUKOTRIENE-ANTAGONIST ICI-204,219 INHIBITS THE EARLY AIRWAY REACTION TO CUMULATIVE BRONCHIAL CHALLENGE WITH ALLERGEN IN ATOPIC ASTHMATICS [J].
DAHLEN, B ;
ZETTERSTROM, O ;
BJORCK, T ;
DAHLEN, SE .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (02) :324-331
[5]   EFFECT OF THE ORAL LEUKOTRIENE ANTAGONIST, ICI 204,219, ON ANTIGEN-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH ASTHMA [J].
FINDLAY, SR ;
BARDEN, JM ;
EASLEY, CB ;
GLASS, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 89 (05) :1040-1045
[6]   ROLE OF LEUKOTRIENES IN EXERCISE-INDUCED ASTHMA - INHIBITORY EFFECT OF ICI-204219, A POTENT LEUKOTRIENE-D4 RECEPTOR ANTAGONIST [J].
FINNERTY, JP ;
WOODBAKER, R ;
THOMSON, H ;
HOLGATE, ST .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (04) :746-749
[7]   Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study [J].
Fish, JE ;
Kemp, JP ;
Lockey, RF ;
Glass, M ;
Hanby, LA ;
Bonuccelli, CM ;
Bronsky, E ;
Condemi, J ;
Goldstein, S ;
Norton, J ;
Rosenthal, R ;
Silvers, W ;
Tinkelman, D ;
Weisberg, S ;
Winder, J .
CLINICAL THERAPEUTICS, 1997, 19 (04) :675-690
[8]  
GLASS M, 1994, J ALLERGY CLIN IMMUN, V93, P295
[9]   THE INFLUENCE OF AGE, DIAGNOSIS, AND GENDER ON PROPER USE OF METERED-DOSE INHALERS [J].
GOODMAN, DE ;
ISRAEL, E ;
ROSENBERG, M ;
JOHNSTON, R ;
WEISS, ST ;
DRAZEN, JM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (05) :1256-1261
[10]  
HOLGATE ST, 1995, ALLERGY S26, V50, P319